Hank, I agree with you. Many people seem to think a BP, or anyone else, would look at the potential and say, this could be a $50 to $100 company in 5 years, I'll pay $20 for it now in spite the fact that it's selling for less than $1 now. That sort of thing just doesn't happen.
If the share price grows to $10, then an offer at $20 is possible. Frankly I believe that LP wants more than that, but whatever her figure is, if she's looking for a buyout at all, she needs to achieve a share price that's at least half the price she's willing to take.
I believe the suit is her first step in coming out, hopefully we'll see more before, or at the Annual Meeting. I won't say it's impossible to reach whatever the level is before approvals, but I really believe we not only need approvals, but we really need proof that other solid cancers will benefit from our vaccines, but when we do that we should be worth well over $20 a share.
GBM alone should be worth $20 a share, but that comes after earnings that justify a $30 billion market cap. Until we have the approvals and growing earnings I don't see a $10 share price unless we have new additional proof that the vaccine works, or is approved, in other solid cancers. If one or more of the regulators gave us a label for solid tumors $50 a share or more ought to easily be in site.
Gary
News 
Market Data 
Discover 
